Medy-Tox Inc Total Liabilities
Medy-Tox Inc total liabilities. Based on the latest financial reports, Medy-Tox Inc (086900) has total liabilities worth ₩119.26 Billion KRW (≈ $80.82 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Medy-Tox Inc (086900) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Medy-Tox Inc (2013–2024)
Total liabilities of Medy-Tox Inc from 2013 to 2024. This chart illustrates how Medy-Tox Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Medy-Tox Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Medy-Tox Inc Competitors by Total Liabilities
The table below lists competitors of Medy-Tox Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Altshuler Shaham Financial LTD
TA:ALTF
|
Israel | ILA1.09 Billion |
|
Guangdong Anjubao Digital Tech
SHE:300155
|
China | CN¥138.36 Million |
|
Tibet Galaxy Science & Technology Development Co Ltd
SHE:000752
|
China | CN¥257.35 Million |
|
Beijing Hezong Science&Technology Co Ltd
SHE:300477
|
China | CN¥5.13 Billion |
|
Uni Chem
KO:011330
|
Korea | ₩74.97 Billion |
|
Sto SE & Co. KGaA
F:STO3
|
Germany | €443.40 Million |
|
A-LIVING SM.CI.SV. H YC 1
F:1V0
|
Germany | €9.07 Billion |
|
Sandhar Technologies Limited
NSE:SANDHAR
|
India | Rs20.99 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Medy-Tox Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 086900 current and non-current assets.
Liquidity & Leverage Metrics
Medy-Tox Inc Total Liabilities Ratios Explained
Medy-Tox Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medy-Tox Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medy-Tox Inc (2013–2024)
The table below shows the annual total liabilities of Medy-Tox Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩144.38 Billion ≈ $97.84 Million |
+5.28% |
| 2023-12-31 | ₩137.14 Billion ≈ $92.94 Million |
-18.49% |
| 2022-12-31 | ₩168.24 Billion ≈ $114.02 Million |
-5.60% |
| 2021-12-31 | ₩178.22 Billion ≈ $120.78 Million |
-21.27% |
| 2020-12-31 | ₩226.37 Billion ≈ $153.41 Million |
+39.40% |
| 2019-12-31 | ₩162.38 Billion ≈ $110.04 Million |
+14.01% |
| 2018-12-31 | ₩142.43 Billion ≈ $96.52 Million |
-24.76% |
| 2017-12-31 | ₩189.29 Billion ≈ $128.28 Million |
+7.34% |
| 2016-12-31 | ₩176.35 Billion ≈ $119.51 Million |
+95.80% |
| 2015-12-31 | ₩90.07 Billion ≈ $61.04 Million |
+3.62% |
| 2014-12-31 | ₩86.92 Billion ≈ $58.91 Million |
+364.10% |
| 2013-12-31 | ₩18.73 Billion ≈ $12.69 Million |
-- |
About Medy-Tox Inc
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and … Read more